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Abstract 
Wolfram syndrome, also known by the mnemonic DIDMOAD (diabetes 
insipidus, diabetes mellitus, optic atrophy and deafness) is a rare progressive 
neurodegenerative disorder. This syndrome is further divided to WFS1 and 
WFS2 based on the different genetic molecular basis and clinical features. In this 
report, we described a known case of Wolfram syndrome requiring anesthesia 
for cochlear implantation. Moreover, a brief review of molecular genetics and 
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Wolfram syndrome was first described by 
physician D J Wolfram and Wagener in 1938 (1-3). 
This autosomal recessive syndrome is also referred to 
as DIDMOAD syndrome, which stands for Diabetes 
Insipidus, Insulin Dependent Diabetes Mellitus, Optic 
Atrophy and Deafness (4). Wolfram is a progressive 
neurodegenerative disorder, mostly the first 
manifestation is diabetes mellitus at the age of 6 years 
and followed by optic atrophy at 11 years. Diabetes 
insipidus and deafness would arise at the second 
decade of life. Other manifestations could include 
atonic bladder, ureterohydronephrosis, myoclonus, 
ataxia, peripheral neuropathy, retinopathy, and 
cataract, neurologic dysfunction leading to sleep 
apnea, depression and psychotic features (1, 4). Life 
expectancy would vary between 25 and 49 years due 
to respiratory and renal failure (1, 2, 4). Its prevalence 
is about 1/100 000 in northern America, 1/770 000 in 
United Kingdom and 1/710 000 in Japanese 
population (1, 3, 5). Diabetes mellitus and optic 
atrophy occurs in all of patients. Prevalence of other 
symptoms are as follow: Hearing loss in 75%, 
Neuropsychiatric illness in 69%, Diabetes Insipidus in 
55%, and renal tract involvement in 45% of patients 
(5). 
There are two types of wolfram syndrome 
based on their genetic cause and clinical feature.  
Wolfram syndrome type 1 is related to WFS1 
Gene in the short arm of chromosome 4 (4p16). This 
gene spans 33.4kb of genomic DNA and consist of 8 
exons (first one is non-coding, 2–7 are coding, and 
the 8th is 2.6kb long) that encodes an 890 amino acid 
polypeptide with 9 transmembrane domains and 
weight of 100kDa (1, 4). Wolframin protein is an 
endoglycosidase H-sensitive membrane glycoprotein 
forming a membrane Ca²⁺ channel in the endoplasmic 
reticulum that could protect neurons and islet β cells 
from premature cell death (1, 4). 
Deficiency in Wolframin results in multisystem 
neurodegenerative process that cause atrophy of optic 
tracts, hypothalamus, and posterior pituitary and 
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cochlear nerve (2). 
There are several mutations detected in this 
genome. All of them are located in exon 8, 
corresponding to the transmembrane region and 
carboxy tail of wolframin protein (1, 4). 
Wolfram syndrome type 2 is caused by 
mutations in CISD2 gene located in 4q24. This gene 
encoded protein named ERIS (Endoplasmic 
Reticulum Intermembrane Small Protein). On the 
other hand as symptoms are restricted to energy 
consumptive cells, it is hypothesized that these genes 
could have effect on mitochondrial functions (6). This 
hypothesis has confirmed by studies on knockout 
mice (7). 
In this type diabetes mellitus occurs in the first 
or second decade; afterwards, visual loss and optic 
atrophy developed in all patients. Sensorineural 
hearing loss could be presented afterwards. Other 
symptoms are urinary tract dilatation and depression 
and upper gastrointestinal ulceration and bleeding, but 
no diabetes insipidus is reported in this type (8).  
In this study we present a Wolfram case that 
candidate for cochlear implantation, anesthetic 
implications and a review about geneticomolcular 
basis of this disease. 
Brief Report 
A 5-years old boy presented with history of 
progressive hearing loss of 3 years duration. He was 
adopted therefore no family history could be acquired. 
His past medical history was significant due to prior 
hyperglycemia during which he was found to be 
diabetic and had been on plain and Lente insulin since 
then. He was admitted once due to weakness with 
diagnosis of severe anemia during which he was 
transfused 1 unit of packed RBC. In these years he 
was under treatment with Vitamin B1 (Thiamine) and 
Vitamin B6 (Pyridoxine) and Vitamin B Complex 
under supervision of pediatric hematologist. Although 
from his second year of life he was using hearing aids 
and attended speech therapy, no significant 
progression was observed therefore he was candidate 
for cochlear implantation. 
On physical examination his visual acuity was 
9/10 in both eyes and esotropia in left eye. Other 
examinations were normal. 
No Auditory Brain Response (ABR) 
waveforms or Distortion Product OtoAcoustic 
Emissions (DPOAE) were observed in audiometry of 
both ears.  
All of his laboratory exams including 
Biochemistry, Complete Blood Count, and 
Coagulation studies were within normal range.  
Midazolam 1mg/IV and Fentanyl 50μg/IV 
prescribed as premedication in the operating room. 
General anesthesia was induced with Propofol 
2mg/kg and atracurium 0.5mg/kg. Anesthesia 
maintained with oxygen, nitrous oxide and Propofol 
100 mcg/kg/min with standard monitoring in place. 
During 150 minutes of surgery to implant cochlea, his 
blood sugars measured each hour were within normal 
range. Meanwhile, he received 20cc/kg/hr of 0.9% 
sodium chloride solution and his urine output was 
preserved 2cc/kg/hr. At last atracurium reversed by 
neostigmine 0.05mg/kg and atropine 0.02mg/kg. 
Discussion 
Wolfram Syndrome can be diagnosed by 
Insulin Dependent Diabetes Mellitus and optic 
atrophy in the first two decades of life. This could be 
the simplest criteria for diagnosis of this syndrome (3, 
9). Early diagnosis helps to initiate treatment sooner, 
therefore avoid serious complications like 
hyperglycemia, hypernatremia, and hyperosmolar 
coma (9). Unfortunately there has not been any 
documentation for treatment or prevention of 
neurodegeneration in these patients and there is no 
therapeutic intervention to expand their life 
expectancy (5, 9). However, early detection, accurate 
management, and prevention of complications with 
careful and repeated examinations of bulbar function 
may improve quality of life and survival of these 
patients(9). 
Loss of islet cells in pancreas which results in 
insulin dependent diabetes mellitus, though to be 
resulted from deficiency in cellular stress response in 
the absence of wolframin (2). 
Symptoms including deafness, blindness, 
diabetes insipidus, and psychotic features are due to 
neurodegenerative basis of this disease which is also 
related to wolframin and WFS1 gene (2). Hilton et al. 
(2) demonstrated that this disease resulted from 
cellular degeneration rather than developmental or 
congenital basis. Diffuse Neurodegeneration in 
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central nervous system could result in 
hypothyroidism, alteration in thermoregulation, and 
gonadal failure (9). 
Death in these patients often results from 
brainstem atrophy, followed by hypoventilation and 
apneic episodes (9). On the other hand, degeneration 
of brainstem and lateral 2/3 of Substantia Nigra and 
cerebellum results in loss of protection of airway that 
leads to aspiration pneumonia. There are some reports 
that imply on correlation of this syndrome with sinus 
tachycardia, atrial or ventricular arrhythmias and 
congenital cardiac abnormalities like Tetralogy of 
Fallot or Pulmonary valve Stenosis (9). 
Anesthetic management of this syndrome 
should focus on glucose control and fluid 
management of DI. As other uncommon 
neurodegenerative diseases, anesthesiologists should 
consider chronic use of anticonvulsant and alteration 
in anesthetics metabolism (10). 
Conclusion 
 Although there has not been any documented 
treatment for wolfram syndrome, early detection and 
managing the complications could extend life 
expectancy of these patients. Further studies by 
addressing geneticomulecular basis, should aim at 
finding new agents which could interrupt the 
degeneration feature of this syndrome.  
Anesthetic management of this syndrome 
should focus on glucose control and fluid 
management of DI. As other uncommon 
neurodegenerative diseases, anesthesiologists should 
consider chronic use of anticonvulsant and alteration 
in anesthetics metabolism (10). 
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